news
Asia-Pacific asthma market will hit $6 billion by 2023
The Asia-Pacific (APAC) asthma therapeutics market is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023...
List view / Grid view
GBI Research
news
First-in-class innovation a key strategy for harsh pharma market environment
16 May 2017 | By Dominic Trewartha, Managing Analyst for GBI Research
First-in-class innovation is a key strategy that companies have been employing to achieve these imperatives. Over recent decades, in addition to an...
news
Head and neck cancer market fertile for investment
8 March 2017 | By GBI Research
A substantial number of first-in-class products in the head and neck cancer pipeline will reach the market over the coming decade, which could potentially transform the clinical and commercial landscape, according to business intelligence firm GBI Research.
news
APAC osteoporosis market to hit $7.7 billion by 2022, says GBI Research
19 July 2016 | By Victoria White, Digital Content Producer
The Asia-Pacific (APAC) osteoporosis market is set to grow from $4.5 billion in 2015 to $7.7 billion in 2022, according to GBI Research...
news
Global urological cancers market to double by 2022, says GBI Research
30 June 2016 | By Victoria White, Digital Content Producer
The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research...
news
Global viral infections market to hit $117.6 billion by 2021, says GBI Research
15 April 2016 | By Victoria White, Digital Content Producer
The global viral infections market will grow from $74 billion in 2014 to $117.6 billion by 2021, according to business intelligence provider GBI Research...
news
Non-haematological cancer treatment market to almost double by 2021
8 April 2016 | By Victoria White, Digital Content Producer
The global treatment market for non-haematological cancers will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, according to GBI Research...
news
US opioid market to hit $17.7 billion by 2021, says GBI Research
31 March 2016 | By Victoria White
The US market for opioids will grow from $11 billion in 2014 to $17.7 billion by 2021, according to business intelligence provider GBI Research...
news
Gastric cancer treatment development shifting to mAbs
17 March 2016 | By Victoria White
The dominance of small molecules in the gastric cancer treatment space could be about to give way to monoclonal antibodies, according to GBI Research...
news
Breast cancer treatment pipeline has over 1,000 drugs in development
1 March 2016 | By Victoria White
The breast cancer treatment pipeline’s exceptional levels of activity and innovation may significantly alter the clinical and commercial landscape, says GBI Research...
news
Parkinson’s disease market to hit $3.2 billion by 2021
25 February 2016 | By Victoria White
GBI Research states that Parkinson’s disease market growth will occur despite the patent expiries of several key products during the forecast period...
news
Alzheimer’s disease treatment market to more than double by 2021, says GBI Research
11 February 2016 | By Victoria White
GBI Research says the impressive growth in the treatment market will be primarily driven by increased disease prevalence during the forecast period...
news
Parkinson’s disease treatment pipeline holds significant potential, says GBI Research
12 January 2016 | By Victoria White
An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets...
news
Breast cancer treatment market to reach $17.2b by 2021, says GBI Research
5 January 2016 | By Victoria White
GBI Research states that this strong growth will be primarily due to substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise over the forecast period due to an aging population, changing lifestyles and higher survival rates...
news
Demand for over-the-counter drugs rising, says GBI Research
23 December 2015 | By Victoria White
Increasing pressures from customers, drug manufacturers and regulators to convert prescription medications to non-prescription status is one of the main drivers of growth within the market...
